These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 32245422

  • 1. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
    Dasari VR, Carey DJ, Gogoi R.
    BMC Cancer; 2020 Apr 03; 20(1):273. PubMed ID: 32245422
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
    Ayyagari VN, Hsieh TJ, Diaz-Sylvester PL, Brard L.
    BMC Cancer; 2017 Jan 13; 17(1):49. PubMed ID: 28086831
    [Abstract] [Full Text] [Related]

  • 3. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
    Rumman M, Buck S, Polin L, Dzinic S, Boerner J, Winer IS.
    Cancer Med; 2021 May 13; 10(10):3373-3387. PubMed ID: 33932119
    [Abstract] [Full Text] [Related]

  • 4. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
    Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM.
    Oncol Rep; 2013 May 13; 29(5):2011-8. PubMed ID: 23467907
    [Abstract] [Full Text] [Related]

  • 5. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
    Yan XD, Li M, Yuan Y, Mao N, Pan LY.
    Oncol Rep; 2007 May 13; 17(5):1163-9. PubMed ID: 17390060
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I, Ladislau-Magescky T, Tessarollo NG, Dos Santos DZ, Gimba ERP, Sternberg C, Silva IV, Rangel LBA.
    Pharmacol Rep; 2018 Jun 13; 70(3):409-417. PubMed ID: 29627688
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.
    Ong PS, Wang XQ, Lin HS, Chan SY, Ho PC.
    Int J Oncol; 2012 May 13; 40(5):1705-13. PubMed ID: 22328352
    [Abstract] [Full Text] [Related]

  • 17. The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma.
    Huang GC, Liu SY, Lin MH, Kuo YY, Liu YC.
    Jpn J Clin Oncol; 2004 Sep 13; 34(9):499-504. PubMed ID: 15466821
    [Abstract] [Full Text] [Related]

  • 18. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha.
    Mizutani Y, Bonavida B.
    Cancer; 1993 Aug 01; 72(3):809-18. PubMed ID: 8334635
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.